Syncom Formulations Gains 5.65%: 5 Key Factors Driving the Week’s Momentum

31 August: Technical Upgrade Spurs Initial Surge

Syncom Formulations began the week on a positive note, closing at Rs.19.48, up 0.10% on the day, while the Sensex declined 0.48%. This modest gain belied a significant technical upgrade from Sell to Hold announced on 24 August, which catalysed renewed buying interest. The stock’s bullish momentum was supported by multiple technical indicators including a bullish MACD on weekly and monthly charts, bullish moving averages, and a strong On-Balance Volume (OBV) profile. Despite a bearish RSI suggesting potential short-term consolidation, the overall technical setup favoured further gains.

2 September: New 52-Week High at Rs.20.89 Amid Market Headwinds

On 2 September, Syncom Formulations surged 6.58% to close at Rs.21.39, hitting a new 52-week high of Rs.20.89 during the session. This marked a continuation of the stock’s strong upward trajectory, outperforming the Sensex which fell 0.44%. The rally was supported by the stock trading above all key moving averages and a bullish MACD, while the sector experienced weakness. The stock’s one-year return of 22.08% contrasted sharply with the Sensex’s negative 4.71%, highlighting its resilience.

3 September: Record High Rs.22.18 and Exceptional Volume Surge

Syncom Formulations reached another milestone on 3 September, hitting a new 52-week high of Rs.22.18. Despite a slight intraday dip of 0.42% to close at Rs.21.30, the stock demonstrated sustained strength with a remarkable volume surge of over 60 lakh shares traded, translating to a traded value of approximately ₹1332.10 lakhs. This volume spike was accompanied by a 47.45% increase in delivery volume compared to the five-day average, signalling strong accumulation by investors. The stock outperformed its Pharmaceuticals & Biotechnology sector peers by 2.75% and the Sensex by 0.41% on the day, underscoring its relative strength amid a cautious broader market.

Technical indicators remained predominantly bullish, with the stock trading above all key moving averages and supported by a bullish MACD and Bollinger Bands. The KST indicator was bullish weekly but bearish monthly, while the RSI remained bearish weekly, suggesting some caution for short-term momentum. The Mojo Score stood at 64.0 with a Hold rating, reflecting a balanced outlook amid strong price action.

3 September: Valuation Upgrade Reflects Heightened Price Attractiveness

Alongside the price and volume surge, Syncom Formulations’ valuation profile shifted from expensive to very expensive on 3 September. The stock’s P/E ratio rose to 23.51, supported by a P/BV of 4.85, reflecting strong market confidence in the company’s growth prospects. Compared to sector peers such as Shukra Pharmaceuticals (P/E 60.53) and Fredun Pharma (P/E 56.23), Syncom’s valuation remains moderate, with a PEG ratio of 0.48 indicating earnings growth is keeping pace with price appreciation.

Financial metrics underpinning this valuation include a robust ROCE of 23.35% and ROE of 18.41%, signalling efficient capital utilisation. Despite the premium multiples, the stock’s one-week gain of 25.60% and one-month return of 62.79% far outpaced the Sensex’s declines, justifying the valuation upgrade. The Mojo Grade upgrade from Sell to Hold on 24 August further supports this improved outlook, though the micro-cap status warrants cautious monitoring.

4 September: Week Closes with Minor Consolidation

On the final trading day of the week, Syncom Formulations closed at Rs.20.56, down 3.47% from the previous day’s close of Rs.21.30. This pullback occurred despite the Sensex gaining 0.19%, reflecting a short-term consolidation after a strong rally. Volume moderated to 15.06 lakh shares, lower than the previous day’s surge, suggesting profit-taking or cautious positioning by investors. The stock’s weekly gain of 5.65% remains a notable outperformance against the Sensex’s 1.11% decline, highlighting the resilience of Syncom’s price action amid mixed market conditions.

Key Takeaways

Strong Outperformance: Syncom Formulations gained 5.65% over the week, significantly outperforming the Sensex’s 1.11% decline, driven by sustained buying interest and technical upgrades.

Technical Momentum: The upgrade from Sell to Hold and bullish signals from MACD, moving averages, and OBV supported the rally, despite some cautionary RSI and KST readings.

Volume Surge and Accumulation: Exceptional volume on 3 September, with delivery volumes rising 47.45%, indicated strong accumulation by investors, reinforcing the price strength.

Valuation Shift: The move to a very expensive valuation grade, with a P/E of 23.51 and P/BV of 4.85, reflects heightened market confidence but warrants monitoring given the micro-cap status.

Short-Term Consolidation: The pullback on 4 September suggests profit-taking or consolidation after a strong rally, highlighting the need for cautious positioning in the near term.

Conclusion

Syncom Formulations (India) Ltd demonstrated a robust performance in the week ending 4 September 2026, marked by multiple new 52-week highs, strong volume-driven rallies, and an upgrade in both technical rating and valuation status. The stock’s 5.65% weekly gain amid a declining Sensex underscores its relative strength and resilience within the Pharmaceuticals & Biotechnology sector. While technical indicators and volume trends signal continued interest, mixed momentum oscillators and a recent pullback advise prudence. The valuation upgrade to very expensive reflects market optimism but also calls for careful monitoring of earnings delivery and sector dynamics. Overall, Syncom remains a notable micro-cap stock exhibiting strong momentum and investor engagement in a challenging market environment.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today